About
A Passion for People = Power for Success
In my role as Life Sciences Industry…
In my role as Life Sciences Industry…
Articles by Jan
Activity
8K followers
-
Jan Ising shared this💬 What does the US Most-Favored-Nation Executive Order mean for European pharma? More than meets the eye. While headlines focus on US drug pricing, the ripple effects across Europe are already being felt. From HTA recalibrations to launch delays and SKU differentiation, European pharma leaders are not just watching—they’re acting. At Accenture, we’ve been working closely with clients to unpack the implications of MFN pricing and help shape proactive strategies. The stakes are high: 🔹 Access risks: MFN-linked pricing could reduce availability of innovative therapies in Europe, especially in public channels and lower-price markets. 🔹 Strategic pivots: Companies are exploring differentiated European labels, outcome-based contracts, and private market alternatives. 🔹 Global coordination: European divisions are aligning with global market access teams to ensure MFN readiness across launch assets. 📣 As Christian Zuberer, Michael Paarmann, and Joshua Salamander Taylor Schwartz, MHA highlighted, this is not just a pricing issue—it’s a strategic inflection point for the industry. If you're navigating similar questions or want to explore how your organization can respond effectively, let’s connect. The time to act is now. #Pharma #LifeSciences #MarketAccess #DrugPricing #HealthPolicy #AccentureStrategy #HealthcareTransformation #Innovation https://lnkd.in/eBHw_TQuJan Ising shared this💊 While the pharma world is watching Pfizer’s, AstraZeneca’s, and Merck Healthcare’s Most-Favored-Nation deals with the US administration, one question looms large: What does the Most-Favored-Nation Executive Order mean for the European pharma business? 📊 The answer: Potentially more than for the US itself. European patients, healthcare systems, market access and commercial strategies may all be affected – and European pharma leaders are already preparing for possible ripple effects. Together with Michael Paarmann and Joshua Salamander Taylor, I’ve spoken with European Market Access executives to understand: 🔹 How are European pharma divisions assessing and preparing for MFN implications? 🔹 Which strategies could mitigate potential disruptions for future launch assets? 🔹 What might this mean for patients and their access to innovation across Europe? 🚀 If you want to learn more about how your peers are acting, or explore what approach could work best for your asset – let’s connect. Jan Ising Dr. André T. Dahinden Johannes Trenka Matthias Tix Zeynep Waelchli Martin F. Brunner Patricia Moubarak Karl-Hubertus Gruber Jean-Baptiste Mayet Ray Pressburger Aiste Hoppe Jason Angelos Florian Leschinsky Jean Liao Petra Seipp Sven Wiedmer Shikha Tyagi Dr. Sven Petersen Michael Brueckner Dr. Sven Kühlborn Daniel Antolin Alexander Lüring #Pharma #LifeSciences #MarketAccess #Pricing #HealthPolicy #MFN #MostFavoredNation #ExecutiveOrder #Accenture
-
Jan Ising shared thisThe Future is Now. The first Executive AI Summit on AI in Healthcare and Medicine marked a pivotal moment in the journey toward precision health and medicine. Co-presented by Stanford’s Biomedical Data Science Department and Accenture, the summit brought together leaders from academia, biopharma, technology, consulting, and healthcare delivery. Together, we explored the immense potential of AI in healthcare—and the critical safety measures needed to guide its responsible evolution. A shared theme emerged: the future of healthcare and Medicine AI will be shaped by cross-sector collaboration, grounded in trust, transparency, and patient-centered outcomes. #AIinHealthcare #PrecisionMedicine #Collaboration #Trust #Accenture #Stanford Please find the full eBooklet https://shorturl.at/joatV Karen Matthys Sylvia Plevritis Laetitia Cailleteau
-
Jan Ising shared thisGreat achievement of the Accenture #Veeva team being recognized in the latest Everest Veeva Service PEAK Matrix Assessment 2025. Congratulations to Rob Saiter and team for being named as the highest-designated leader. Well done and many thanks!Jan Ising shared thisWhen 35 global Veeva service providers were evaluated, Accenture was named the highest-designated Leader in Everest Group’s Veeva Services PEAK Matrix® Assessment 2025, positioned at the top for both the Vision & Capability and Market Impact axes. Everest Group cited our scale and delivery rigor as a premier-tier Veeva partner, our deep implementation experience, cross-Vault expertise, and our global delivery footprint. They also noted the collaborative execution and technical certifications that position us as a trusted partner for large-scale transformation programs across both commercial and development clouds. This recognition reflects the dedication of our teams and the trust our clients place in us to deliver end-to-end solutions that help drive transformation across the life sciences value chain. https://lnkd.in/gXyPas3c As life sciences organizations continue their transformation journeys, what qualities do you believe matter most in a trusted partner? #LifeSciences #PEAKMatrix #DigitalTransformation Dr. Petra Jantzer, Jan Ising, Brad Michel, Craig Robertson, Gro Blindheim, Rich Sherman, Lauren Hsu, Sven Wiedmer, Thomas Philipose, Selen Karaca-Griffin, Richard Chen, Sascha Thiery, Stuart Henderson
-
Jan Ising shared thisDid you know that 94% of HCPs and 99% of field team members are already using or planning to use AI tools in their daily work? But here’s the twist — their visions for how #AI will deliver value are not the same. I’m thrilled to invite you to the third edition of #FutureMindsInHealth 2025, hosted by #Accenture — a virtual event that dives deep into these evolving perspectives. 🧠 What to expect: Fresh insights from two new research studies — one with hundreds of biopharma field team members, and another with over 500 HCPs A forward-looking discussion on redefining customer engagement in 2025 and beyond 📅 Date: September 10, 2025 🕔 Time: 17:00–18:00 CET 📍 Location: Online (MS Teams) 🎙️ Speakers: Dr. Dr. André T. Dahinden & Christoph Loeffler 💬 I’ll be joining the panel for the Q&A — looking forward to exchanging thoughts with you! This is a re-run of our June event — a second chance for those who missed it. Interested in joining? Drop me a message and I’ll send you the invite. #FutureMindsInHealth #FieldEngagement #HCPExperience #LifeSciences #Accenture #AI #CustomerStrategy #HealthInnovation #PharmaLeadership #CommercialExcellence
-
Jan Ising shared thisThanks Gro Blindheim and the entire Accenture for getting this organized. Looking forward for this great panel line-up. #Dreamforce2025 #LifeSciencesJan Ising shared thisI am very excited to be hosting the upcoming Life Sciences fireside chat at Dreamforce 2024: featuring leaders from Bayer, Novartis and Takeda to talk about the Future of Customer Engagement. Please join us next week on Sept 18 at 2:00 PM at Moscone West. 🚀 Learn how these industry pioneers are transforming customer engagement in Life Sciences. Key Themes: - Commercial opportunities arising from the new technology frontier - What are the barriers to overcome to harness these new opportunities - How ready are business and IT organizations to take on this challenge - How do organizations approach the execution, and readiness … and more Speakers: Garth Hemmingsen, Head of Customer Experience Innovation at Takeda, Patrick Moeller, Interim CIO and Global Head of Commercial IT & Digital Pharma at Bayer, Mary Treacy, Head DD&IT US & International, Novartis 📅 When & Where: Sept 18, 2:00 PM PDT, Moscone West, L3, Room 3016 Check out #Accenture’s latest and greatest sessions on the Dreamforce stage here: https://lnkd.in/dSzmFDsj 🔗 Add this to your Agenda builder here: https://lnkd.in/dJhsjJMh 📣 Arrive early, seats are first-come, first-served! #HealthcareInnovation #DigitalHealth #DF24 Lauren Hsu, Rich Sherman,Sven Wiedmer, Dr. Petra Jantzer, Stephanie Sadowski, Jan Willem Van Den Bremen, Christina Raab, Jan Ising, Shishir Lohmror, Ray Pressburger
-
Jan Ising shared thisHFS Research kindly shared a report on Accenture’s investment in QuantHealth via Accenture Ventures boosting our pharmaceutical and biontech offerings in improving the predictability of drug trials. Thanks Mayank Madhur for this good read.Accenture boosts pharmaceutical and biotech with niche offeringsAccenture boosts pharmaceutical and biotech with niche offerings
-
Jan Ising shared thisGreat podcast by our colleague Tom Lehmann together with Chris Braithwaite from Novartis to drive #digitaltransformation focusing on change management as an imperative.Jan Ising shared thisIt's easy to see digital transformation as an opportunity, but Chris Braithwaite, Novartis Global Head of Drug Development, Digital and IT looks at it differently. In the latest Driving Digital in Biopharma podcast, we spoke about how he believes #digitaltransformation is about using data to make the right decisions and augmenting human decision-making to make people more effective. This transformation is a delicate balancing act and can lead to better outcome for patients, reduce R&D cycle times, and make medicines more affordable. Listen to the full episode: https://lnkd.in/e3hWE2TF Dr. Petra Jantzer Ray Pressburger Jan Ising Rob Saiter
-
Jan Ising shared thisI am thrilled that Accenture is a part of this venture AstraZeneca to accelerate innovation and raise standards within the digital health technology sector. Good luck Sean Connolly with this mission and looking forward creating the relevant #patientimpactJan Ising shared thisToday we announce the launch of Evinova, a health-tech business within the AstraZeneca Group to accelerate the delivery of better health outcomes and propel the life-sciences sector forward. With strategic collaborations in place with Parexel and Fortrea, Evinova offers globally-scaled digital solutions to the life sciences and healthcare sector to accelerate the development of life-changing medicines. Learn more here: https://learn.az/6047u2L7R!
-
Jan Ising shared this“Together with ConcentricLife, we will create a powerful capability to shape the future of health experiences.” Like David Droga, I’m buzzing over Accenture Song’s acquisition of ConcentricLife. No doubt: It can only amplify our commitment to revolutionizing healthcare. This partnership is set to ignite transformative change, combining our robust tech expertise with ConcentricLife’s innovative healthcare marketing strategies. What does this mean for the market? Expect ground-breaking approaches in patient care, enhanced digital experiences, and a wave of innovation in health communications. We’re not just changing the game; we’re making it more dynamic, accessible, and patient-centric. Find out what the company is all about: www.concentric.life Accenture DACH Accenture
Jan Ising commented on a post
3d
Well done and many thanks to Maxim Lewinz and the entire #Accenture #LifeSciences team. Indeed, worse the time to read and get familiar with
Jan Ising commented on a post
1w
Ray Pressburger Looking forward to continue our journey as the global #LifeSciencesFamily that we have grown to over the years. It's great to see us all focus on our clients and colleagues to make this success last - always in favor of the patients that our clients serve. All the best! And as you right said - hug thank to Dr. Petra Jantzer for guiding us in times of massive challenges and still being the leader required to achieve the impact we always hoped for. The fantastic new ride shall start now!
-
Jan Ising liked thisA concise and highly relevant PoV from my #Reinventor colleague #MaximLewinz on how to financially quantify the impact of #AI in Pharma. Worth five minutes for anyone who wants to understand what investors increasingly expect to see as AI moves from promise to performance. The message is clear: we have moved beyond hype. With AI adoption scaling, value creation and measurable returns now matter most. Florian Leschinsky Zeynep Waelchli Sven Gudehus Alexander A. Huber Jan Ising Dr. Timo Würz Dr. André T. Dahinden Christian Zuberer Patricia Moubarak Karl-Hubertus GruberJan Ising liked thisAI prediction: In 2026, more pharma companies will publish their AI value in real currency. Investors want proof of value, not stories. So far, only a handful of companies can point to published AI financial impact. Here are the three biggest blockers I see at companies that struggle: 1️⃣ The AI value attribution problem is not solved 2️⃣ AI value forecasts are unreliable 3️⃣ AI value governance is weak Contrast that with AI leaders who track and publish their AI value. They take AI value measurement seriously and have a highly disciplined AI value tracking organization and governance. Already today, we see these companies outperforming the laggards. Or as a client said to me: "We need to treat AI value like any other financial metric. Measured, tracked, and shared." How are you measuring and reporting AI value in your organization? Let’s continue the conversation. --- 👉 Follow for more on AI value in pharma.
-
Jan Ising liked thisJan Ising liked thisOut of office. Into the mountains. This past weekend, away from inboxes, models, and news cycles, I was reminded why stepping away matters. Skinning up before sunrise. Crossing a glacier under a still-cold sky. Roping up through a rocky couloir where every step demands full attention. Then — the summit, and a view across the Alps that puts everything in proportion. The pace of change in our industry right now is extraordinary. AI capabilities that felt like distant research twelve months ago are reshaping how clients operate, how teams work, how we deliver. It is exciting. It is also relentless. Resilience is not built at the desk. It is built in the moments when we deliberately unplug — when the only signal that matters is the crunch of snow under your skis, the rhythm of your breath, and the trust you place in the person on the other end of the rope. A few things the mountains keep teaching me: Perspective scales with altitude. Problems that feel all-consuming at sea level look different from 3,500 metres. Progress is a function of pace, not panic. You do not sprint up a glacier. You find a sustainable rhythm and you keep moving. The rope matters. Whatever the summit, you get there with others (Roman Hermann), or you do not get there safely at all. Back at my desk this week, energized, clearer, and grateful. To clients navigating transformation, to colleagues pushing the frontier of what AI can do for industry — the work continues, and it is better work when we give ourselves room to breathe. Where do you go to recharge? #Leadership #Resilience #Skitouring #SwissAlps
-
Jan Ising liked thisJan Ising liked thisMittwoch, Accenture Campus Kronberg - Eröffnung unseres Kompetenzzentrums Digitale Souveränität. Digitale Souveränität ist kein Buzzword: Unternehmen und Institutionen brauchen einen soveränen Digitalen Kern, der Wahlfreiheit und Resilienz sicherstellt und es erlaubt technologische Abhängigkeiten aktiv zu gestalten. Gemeinsam mit starken Stimmen aus Politik, Wirtschaft und Technologie – darunter Melanie Kehr und Staatsministerin Prof. Dr. Kristina Sinemus – haben wir diskutiert, wie digitale Technologien so eingesetzt werden können, dass sie strategische Handlungsfähigkeit, Wettbewerbsfähigkeit und Innovationskraft erhalten und stärken. Im Kompetenzzentrum bündeln wir die Expertise zu den relevanten Aspekten Digitaler Souveränität von Strategie, Operating Model und Compliance über Cyber-Security, Architektur und Technologie bis zum Ökosystem souveräner Lösungen. Mit einem klaren Ziel: Digitale Souveränität praxisnah umsetzbar machen. Danke an alle Beteiligten für den Austausch, die Impulse und den gemeinsamen Anspruch, die Zukunft aktiv zu gestalten. Und ganz großen Dank an das #Team um Timo Nink, das den Launch so exzellent und kompetent vorbereitet hat. Ihr habt grossartiges geleistet! Ich freue mich auf viele spannende Workshops mit unseren Kunden, um von der Diskussion über Digitale Souveränität in die Umsetzung zu kommen. Christina Raab Corinna Krezer Dr. Jochen Malinowski Boris von Chlebowski Mike Buettner Karsten Merschjan Franziska Bauer Tobias Olbrück Axel Kistner Andriy Chortkivskyy ...und viele mehr. #DigitaleSouveränität #DigitalCore #Innovation #KI #Cloud #Cybersecurity #AccentureDACH
-
Jan Ising liked thisJan Ising liked thisFirst weeks at Genioo - and it already feels different After many years in global Consulting, these past weeks have been a strong reminder of what really drives impact: working with clients to make change happen - and not just designing it. At Genioo , that mindset is real. We combine strategy with execution, partner closely with leadership and teams, and stay focused on one thing: delivering together tangible, sustainable results and value. What makes it special for me is the people. Experienced practitioners, entrepreneurial spirit, and a shared commitment to outcomes over theory. On a personal note, the move brings me closer again to what I enjoy most: helping clients in critical moments and building something with long term ambition. Excited for what lies ahead. #Genioo #LifeSciences #Transformation #Execution #Leadership
-
Jan Ising liked thisJan Ising liked this𝗔𝗰𝗰𝗲𝗻𝘁 𝗼𝗻 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 ’𝟮𝟲 𝗶𝘀 𝗹𝗶𝘃𝗲. 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗼𝗽𝗲𝗻. 📅On 𝗝𝘂𝗻𝗲 𝟭𝟳, 𝟮𝟬𝟮𝟲 we bring together business leaders, experts, policymakers, and innovators for the 3rd time to our 𝘃𝗶𝗿𝘁𝘂𝗮𝗹 and 𝗼𝗽𝗲𝗻 to all 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝘂𝗺𝗺𝗶𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀. How? - with a 𝟭𝟰 𝗵𝗼𝘂𝗿 𝗴𝗹𝗼𝗯𝗮𝗹 𝗹𝗶𝘃𝗲 𝘀𝘁𝗿𝗲𝗮𝗺, - from 𝗦𝗶𝗻𝗴𝗮𝗽𝗼𝗿𝗲 𝘁𝗼 𝗡𝗲𝘄 𝗬𝗼𝗿𝗸, - with 𝟭𝟳 𝗰𝘂𝗿𝗮𝘁𝗲𝗱 𝘀𝗲𝘀𝘀𝗶𝗼𝗻𝘀 across industries and functions, - more than 40 𝘃𝗼𝗶𝗰𝗲𝘀 from business, academia, and civil society - on 𝘁𝗼𝗽𝗶𝗰𝘀 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝗳𝗼𝗿 𝗮𝗹𝗹 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝘀 like Procurement, R&D, IT, Finance, Strategy, Sustainability, Sales, HR - with 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗳𝗼𝗿𝗺𝗮𝘁𝘀 e.g. case studies, speed dating, panels, fire side chats, PowerTalk Addressing the most pressing challenges to become a more sustainable business by delivering solutions that 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗿𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝗰𝗲, 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀, 𝗮𝗻𝗱 𝗶𝗺𝗽𝗮𝗰𝘁. First confirmed speakers include: Daniella Vega, Senior Vice President Health & Sustainability Ahold Delhaize Eva Zabey, CEO Business for Nature Kunal Chandra, Chief Strategy & Sustainability Officer RWE Mehul Thakkar, Sustainability & ESG Lead for Asia Pacific, Japan and China Dell Technologies Dirk Voeste, Senior Vice President Strategy & Sustainability, Volkswagen Group Pierre-Francois Thaler, Co-Founder & Co-CEO EcoVadis Claudia von Bothmer Director Corporate Responsibility & Sustainability Telefónica Germany ✨ Many more leaders from business, academia, and civil society will follow and be announced soon! 💡 𝗙𝗿𝗼𝗺 𝗔𝗜, 𝗲𝗻𝗲𝗿𝗴𝘆 𝗮𝗻𝗱 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝘁𝗼 𝗰𝗶𝗿𝗰𝘂𝗹𝗮𝗿𝗶𝘁𝘆, 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻𝘀, 𝗱𝗮𝘁𝗮, 𝗳𝗶𝗻𝗮𝗻𝗰𝗲, 𝗮𝗻𝗱 𝗴𝗲𝗼𝗽𝗼𝗹𝗶𝘁𝗶𝗰𝘀 – Accent on Sustainability ’26 tackles the questions, leaders cannot afford to postpone. 👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 and build your personal agenda of the day during registration. Participation is free and virtual. 𝗣𝗹𝗲𝗮𝘀𝗲 𝗳𝗶𝗻𝗱 𝘁𝗵𝗲 𝗹𝗶𝗻𝗸 𝘁𝗼 𝗼𝘂𝗿 𝗔𝗰𝗰𝗲𝗻𝘁 𝗼𝗻 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 ’𝟮𝟲 𝗪𝗲𝗯𝘀𝗶𝘁𝗲 here https://lnkd.in/emyz5HvT and 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝗼𝗺𝗺𝗲𝗻𝘁. Christina Raab Wytse Kaastra Rachel Barton Sanjay Podder Jens C. Laue Tobias Gehlhaar Juergen Reers Anna Belvén Töndevold Jon Williams Lauren Ing Sundeep Singh Priyanka Abbi Shruti Goel Matias Pollmann-Larsen Silvia Rigato Rüdiger Stern Tobias Regenfuss Dr. Kate Sikavica Dr. Thomas Melde Cara Smyth #AccentOnSustainability #FutureOfBusiness #SustainableBusiness #Resilience #Innovation #Reinvention #AccentureExpertView
-
Jan Ising liked thisExcited to share that today is my first day as Chief AI and Digital Officer at ELIQUENT Life Sciences. I spent the last several years at Accenture helping biopharma and medtech organizations build and scale AI capabilities across R&D — work I'm incredibly proud of, alongside talented individuals and partners. Grateful for that chapter. What drew me to Eliquent is a team with deep domain expertise, rigor, and trust in areas of life sciences where AI hasn't gotten as much attention yet, but where the potential for transformation is enormous. Regulatory, quality, and safety are complex, high-stakes domains, and I believe Eliquent's people and experience are what it takes to unlock the full potential of AI in these areas. Looking forward to what's next. More to come.Jan Ising liked thisAI is rapidly transforming how life sciences organizations navigate regulatory, quality, and safety complexity. At ELIQUENT Life Sciences, we see both the opportunity and the challenge this brings, and expanding our capabilities to support our clients is a key priority. As part of this focus, we are pleased to announce the appointment of Andy Greenberg as Chief AI and Digital Officer. Andy brings more than 25 years of experience across life sciences, healthcare, and digital innovation. In his most recent role, he led AI and data for life sciences R&D in North America at Accenture, helping biopharma and medtech organizations build and scale AI driven capabilities across the development lifecycle. His leadership will play an important role in advancing our AI and digital capabilities and strengthening how we support clients as they navigate the increasingly complex regulatory, quality, and safety environment. Welcome to the team, Andy.
-
Jan Ising liked thisThank you to Advance – Gender Equality in Business for this thoughtful post and for continuing to elevate this conversation. AI is a defining moment for women because early engagement shapes what becomes possible. This isn’t about becoming experts overnight — it’s about stepping in, experimenting, and staying close to the change. Confidence isn’t a prerequisite for AI; it’s the result. What makes this moment truly consequential is that digital proficiency compounds. For women, starting now builds agency, influence, and choice over time. I’m truly grateful to be part of a community that’s leaning in early and shaping what comes next — together.Jan Ising liked thisIf you’ve been hesitating about how — or when — to start using AI, this keynote from our International Women’s Day celebration is the nudge you’ve been waiting for. In “𝐊𝐞𝐞𝐩 𝐨𝐧 𝐒𝐡𝐚𝐩𝐢𝐧𝐠: 𝐖𝐡𝐲 𝐓𝐡𝐢𝐬 𝐃𝐢𝐬𝐫𝐮𝐩𝐭𝐢𝐨𝐧 𝐈𝐬 𝐘𝐨𝐮𝐫 𝐌𝐨𝐦𝐞𝐧𝐭, Dr. Petra Jantzer, Global Life Sciences Lead at Accenture, speaks directly to women navigating today’s transformation. Her core message is clear and empowering: “𝐘𝐨𝐮 𝐝𝐨𝐧’𝐭 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐦𝐚𝐬𝐭𝐞𝐫 𝐀𝐈 𝐛𝐞𝐟𝐨𝐫𝐞 𝐲𝐨𝐮 𝐮𝐬𝐞 𝐢𝐭. 𝐘𝐨𝐮 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐮𝐬𝐞 𝐢𝐭 𝐭𝐨 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐦𝐚𝐬𝐭𝐞𝐫𝐲.” Petra also shares five concrete actions you can take to start shaping your future today and captures the urgency of this moment with one striking insight: 💡 “𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐩𝐫𝐨𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐢𝐬 𝐭𝐡𝐞 𝐧𝐞𝐰 𝐜𝐚𝐫𝐞𝐞𝐫 𝐜𝐮𝐫𝐫𝐞𝐧𝐜𝐲 – 𝐢𝐭 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐬 𝐟𝐨𝐫 𝐭𝐡𝐨𝐬𝐞 𝐰𝐡𝐨 𝐢𝐧𝐯𝐞𝐬𝐭 𝐞𝐚𝐫𝐥𝐲. 𝐈𝐭 𝐝𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐞𝐬 𝐭𝐡𝐞 𝐬𝐚𝐯𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐨𝐬𝐞 𝐰𝐡𝐨 𝐰𝐚𝐢𝐭.” 📺 Watch the recording and then put the insights into actions: https://lnkd.in/emG-F2ig #KeepOnAdvancing #IWD2026
Experience & Education
-
Accenture
View Jan’s full experience
See their title, tenure and more.
or
Other similar profiles
-
Bernd Karl
Bernd Karl
Strategy and Consulting for Health and Public Service and Delivery Lead of large-scale projects in digital transformation programs. I have 20 years experience in designing IT-solutions and managing large-scale IT transformation projects. I mainly worked in the Digital Government and E-Health areas and have deep industry skills in Human Services, Social Services, and Health specialising on Digital Customer, Digital Enterprise, and Business Process Optimization & Management. I hold a Master's degree in Medical Informatics and Telemedicine, and PMI Project Management Professional (PMP).
Explore more posts
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content